FDA approves first interchangeable biosimilar insulin product
The Food and Drug Administration this week the first interchangeable biosimilar insulin product to treat diabetes. The product (Semglee) can be substituted for the previously approved biological insulin product Lantus to treat type 1 diabetes in children and type 1 or 2 diabetes in adults.
鈥淭his is a momentous day for people who rely daily on insulin for treatment of diabetes, as biosimilar and interchangeable biosimilar products have the potential to greatly reduce health care costs,鈥 said Acting FDA Commissioner Janet Woodcock, M.D.
For more information on biosimilar and interchangeable products, see the new FDA for health care providers.
Related News Articles
Headline
AHA podcast: Food as Medicine 鈥 How Cleveland Clinic Is Nourishing Community HealthVickie Johnson, executive vice president and chief community officer at鈥
Headline
As part of Community Health Improvement Week June 9-13, two experts from Corewell Health share how an impactful health care ecosystem model is supporting local鈥
Headline
With June 9-13 being Community Health Improvement Week, three experts from HonorHealth discuss how the health care network is addressing community needs beyond鈥
Blog
Even before the COVID pandemic, the mental health and wellness of our young people was failing. The pandemic exacerbated the crisis and made it difficult for鈥
Headline
A new AHA video highlights how Corewell Health is transforming youth behavioral health care access in rural Michigan through school-based clinics and鈥
Headline
The Food and Drug Administration May 16 announced it cleared the first blood test to diagnose Alzheimer鈥檚 disease. The test, created by Fujirebio Diagnostics,鈥